丙型肝炎治疗的过去、现在和未来

宁会彬; 尚佳

doi:10.3969/j.issn.1001-5256.2017.06.012

丙型肝炎治疗的过去、现在和未来

DOI: 10.3969/j.issn.1001-5256.2017.06.012

宁会彬,
尚佳

河南省人民医院感染科

基金项目:

河南省科技厅医学科技攻关计划项目(152102310135)；

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2466
- HTML全文浏览量: 40
- PDF下载量: 552
- 被引次数: 0
出版历程
- 出版日期: 2017-06-20

The past, present and future of hepatitis C treatment

Research funding:

摘要

摘要: 丙型肝炎及其并发症是我国肝病防治的重点之一,从20年前的临床实践到现在近乎100%的治愈率,丙型肝炎诊疗的规范化、大量的科学研究以及药物的研发是HCV得以清除的根本。HCV的清除离不开直接抗病毒药物,HCV的清除并不等同于慢性丙型肝炎治愈,在当今直接抗病毒药物应用下取得高持续病毒学应答率的丙型肝炎患者仍应关注其长期预后,如何正确看待和合理应用丙型肝炎仍是目前需要探讨的热点问题。
- 肝炎,丙型 /
- 抗病毒药 /
- 治疗
Abstract: Hepatitis C and its complications are one of the highlights in liver disease prevention and control in China, and from the clinical practice 20 years ago to a cure rate of nearly 100% at present, standardized diagnosis and treatment of hepatitis C, a large number of scientific studies, and drug research and development are the basis for the clearance of HCV. Direct-acting antiviral agents play an important role in the clearance of HCV, and the clearance of HCV does not equal to the cure of chronic hepatitis C. For patients with hepatitis C who have achieved a high sustained virologic response rate after using direct-acting antiviral agents, their long-term prognosis should be taken seriously. Correct and reasonable application of hepatitis C treatment is still a hot issue that needs to be discussed at present.
- hepatitis C /
- antiviral agents /
- therapy

HTML全文

参考文献(20)

[1]UMAR M, KHAN AG, ABBAS Z, et al.World Gastroenterology Organisation global guidelines:diagnosis, management and prevention of hepatitis C April 2013[J].J Clin Gastroenterol, 2014, 48 (3) :204-217.

[2]DUAN ZP, JIA JD, HOU J, et al.Current challenges and the management of chronic hepatitis C in mainland China[J].J Clin Gastroenterol, 2014, 48 (8) :679-686.

[3]Chinese Society of Hepatoloy and Chinese Society of Infection Dieases, Chines Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[4]LISTED N.Virus interference:I.The interferon.By Alick Isaacs and Jean Lindenman, 1957[J].CA Cancer J Clin, 1988, 38 (5) :280-290.

[5]DAVIS GL, BALART LA, SCHIFF ER, et al.Treatment of chronic hepatitis C with recombinant interferon alfa[J].N Engl J Med, 1990, 321 (22) :1501-1506.

[6]LEE SS, BAIN VG, PELTEKIAN K, et al.Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice[J].Aliment Pharm Thera, 2006, 23 (3) :397-408.

[7]RAO H, WEI L, SHANG J, et al.Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J].J Gastroenterol Hepatol, 2014, 29 (3) :545-553.

[8]DAI CY, CHUANG WL, YU ML.Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3[J].Hepatology, 2014, 60 (6) :2129-2130.

[9]AASLD/IDSA HCV Guidance Panel.Hepatitis C guidance:AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J].Hepatology, 2015, 62 (3) :932-954.

[10]European Association for Study of Liver.EASL recommendations on treatment of hepatitis C 2016[EB/OL].[2017-1-20].http://www.easl.eu/medias/cpg/HCV2016/English-report.pdf.

[11]World Health Organization.Guidelines for the screen, care and treatment of persons with chronic hepatitis C infection[EB/OL].[2017-1-20].http://www.who.int.

[12]American Association for the study of Liver Disease and Infectious Diseass Society of America.HCV Guidance:recommendations for testing, managing, and treating hepatitis C[EB/OL].[2017-1-20].http://hcvguidelines.org/.

[13]SIEDERDISSEN CHZ, MAASOUMY B, MARRA F, et al.Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort[J].Clin Infect Dis, 2016, 62 (5) :561-567.

[14]FELD JJ, KOWDLEY KV, COAKLEY E et al.Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin[J].N Engl J Med, 2014, 370 (17) :1594-1603.

[15]LI JZ, CHAPMAN B, CHARLEBOIS P, et al.Comparison of illumina and 454 deep sequencing in participants failing raltegravirbased antiretroviral therapy[J].PLo S One, 2014, 9 (3) :e90485.

[16]CONTI F, BUONFIGLIOLI F, SCUTERI A, et al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals[J].J Hepatol, 2016, 65 (4) :727-733.

[17]van der MEER AJ, FELD JJ, HOFER H, et al.Risk of cirrhosisrelated complications in patients with advanced fibrosis following hepatitis C virus eradication[J].J Hepatol, 2016.[Epub ahead of print]

[18]AFDHAL N, ZEUZEM S, KWO P, et al.ION-1 Investigators.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection[J].N Engl J Med, 2014, 370 (17) :1889-1898.

[19]AFDHAL N, REDDY KR, NELSON DR, et al.ION-2 Investigators.Ledipasvir and sofosbuvir for previously treated HCV genotype1 infection[J].N Engl J Med, 2014, 370 (17) :1483-1493.

[20]WEI L, HAN T, YANG D, et al.Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-na6ve patients in China and South Korea[J].J Gastroenterol Hepatol, 2016, 31 (5) :912-920.

施引文献

资源附件(0)

访问统计